A Phase 2 interventional study of 4 mg elamipretide and 40 mg elamipretide in Heart Failure, sponsored by Stealth BioTherapeutics Inc.. Completed at 15 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-05-14.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 449 studies in Heart Failure with a site in Italy — 111 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.
Among the 449 studies in Heart Failure with a site in Italy, this one is the 213th largest by enrollment of the 292 interventional ones that give a count, is one of 17 that started in 2016, is one of 38 in phase 2, and was the 194th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →111 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:
Niguarda Hospital · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 29 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Bayer · Sites in Italy, United States, Argentina and 20 more countries
Ages up to 18
Biotronik SE & Co. KG · Sites in Italy, Australia, Austria and 10 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
449 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 48 · Phase 3 85 · Phase 4 36
First in 1983; this study’s year is marked. 17 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is close to the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 200 across the 292 interventional studies, 353 across the 152 observational. Of the 252 that completed or were terminated, 91 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
205 of 449 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
36 of the studies in Heart Failure with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
| NCT03775161Vectorious Medical Technologies Ltd.V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure | 2026-12 |
| NCT03994874Iperboreal Pharma SrlPeritoneal Ultrafiltration in Cardio Renal Syndrome. | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 449 studies in Heart Failure with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF). After completing the Screening period, a total of 71 subjects were randomized, in a 1:1:1 ratio, to receive either placebo, 4 mg elamipretide, or 40 mg elamipretide once daily for 28 consecutive days.
Each treatment group went through 3 distinct periods: Screening, Treatment, and Follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of must agree to use 1 of the following methods of from the date they sign the ICF until two months after the last dose of study medication:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg elamipretide once daily for 28 consecutive days
Drug: 4 mg elamipretide
40 mg elamipretide once daily for 28 consecutive days
Drug: 40 mg elamipretide
Placebo once daily for 28 consecutive days
Drug: Placebo
Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
Also known as: MTP-131, Bendavia
Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
Also known as: MTP-131, Bendavia
Subcutaneous injection of placebo administered once daily for 28 consecutive days
Change in Left Ventricular End Systolic Volume (ml)
Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Left Ventricular Ejection Fraction (% of Blood Volume)
Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI
Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Left Ventricular Stroke Volume (ml)
Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Left Ventricular Cardiac Output (L/Min)
Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Left Ventricular Myocardial Mass (g)
Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Right Ventricular End Systolic Volume (mL)
Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Right Ventricular End Diastolic Volume (mL)
Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Right Ventricular Ejection Fraction (% Blood Volume)
Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
Time frame: Baseline to Week 4
Change in Early and Late Mitral Inflow Velocity Ratio
Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')
Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Left Atrial Volume (mL)
Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Left Ventricular Global Longitudinal Strain Assessment (%)
Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography
Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography
Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Biplane Ejection Fraction (mL)
Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Left Ventricular Mass Assessment (g)
Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Tricuspid Regurgitation Severity Assessment (cm²)
Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Right Ventricular Fractional Area (%)
Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Right Ventricular Systolic Pressure (mmHg)
Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
Change in Mitral Regurgitation Severity (cm²)
Change in Mitral Regurgitation Severity as measured by cm² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
Time frame: Baseline to Week 4
| Milestone | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Started | 23 | 24 | 24 |
| Completed | 22 | 24 | 24 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular End Systolic Volume (ml) | -4.4 ± 6.50 | -1.2 ± 9.04 | -3.8 ± 5.85 |
Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| percentage of blood volume | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular Ejection Fraction (% of Blood Volume) | 2.2 ± 2.43 | 1.5 ± 2.82 | 2.3 ± 3.69 |
Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI | -2.8 ± 9.50 | 0.5 ± 11.96 | -2.2 ± 9.77 |
Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular Stroke Volume (ml) | 3.1 ± 9.23 | 3.7 ± 9.36 | 3.0 ± 13.14 |
Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| L/min | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular Cardiac Output (L/Min) | 0.21 ± 1.264 | -0.01 ± 1.004 | 0.27 ± 0.860 |
Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| grams | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular Myocardial Mass (g) | 0.0 ± 2.82 | -0.4 ± 2.78 | -0.0 ± 2.26 |
Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Right Ventricular End Systolic Volume (mL) | -0.9 ± 4.21 | -0.8 ± 4.94 | -0.6 ± 3.72 |
Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Right Ventricular End Diastolic Volume (mL) | 0.5 ± 9.70 | -1.2 ± 10.72 | -0.0 ± 7.61 |
Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.
| percentage of blood volume | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Right Ventricular Ejection Fraction (% Blood Volume) | 1.4 ± 3.05 | 0.4 ± 2.10 | 1.2 ± 3.33 |
Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| ratio | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Early and Late Mitral Inflow Velocity Ratio | -0.04 ± 0.185 | -0.03 ± 0.329 | -0.07 ± 0.528 |
Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| ratio | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e') | -0.94 ± 3.244 | 0.47 ± 4.359 | -0.20 ± 4.287 |
Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Atrial Volume (mL) | -3.4 ± 6.85 | -0.2 ± 4.41 | 1.6 ± 4.02 |
Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| percentage of myocardial length change | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular Global Longitudinal Strain Assessment (%) | -1.76 ± 1.993 | -1.50 ± 2.721 | -1.46 ± 2.362 |
Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography | -1.1 ± 16.29 | 1.6 ± 13.68 | 2.0 ± 15.29 |
Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography | -1.9 ± 11.59 | -0.5 ± 7.91 | 0.6 ± 10.31 |
Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| mL | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Biplane Ejection Fraction (mL) | 1.8 ± 2.94 | 2.0 ± 2.82 | 1.5 ± 4.22 |
Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| grams | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Left Ventricular Mass Assessment (g) | 3.0 ± 18.26 | -4.2 ± 18.55 | -0.7 ± 21.99 |
Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| cm² | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Tricuspid Regurgitation Severity Assessment (cm²) | -1.03 ± 1.334 | 0.25 ± 1.336 | -0.30 |
Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| percentage of area | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Right Ventricular Fractional Area (%) | 0.1 ± 10.82 | 0.1 ± 8.79 | 0.9 ± 8.93 |
Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| mmHg | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Right Ventricular Systolic Pressure (mmHg) | 5.7 ± 16.19 | -1.5 ± 6.63 | -7.0 ± 25.61 |
Change in Mitral Regurgitation Severity as measured by cm² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.
| cm² | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| Change in Mitral Regurgitation Severity (cm²) | 0.70 ± 2.668 | -0.71 ± 2.200 | -0.73 ± 1.834 |
Collected over 10 weeks (The AE reporting period began when the subject signed the ICF and continued through the clinical study's post treatment follow-up period, defined as 14 days after last administration of study medication.). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4 mg Elamipretide | 0/22 (0%) | 0/22 (0%) | 9/22 (40.9%) |
| 40 mg Elamipretide | 0/25 (0%) | 1/25 (4%) | 16/25 (64%) |
| Placebo | 0/24 (0%) | 0/24 (0%) | 10/24 (41.7%) |
| Event | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| VestibularNervous system disorders | 0/22 | 1/25 | 0/24 |
| Event | 4 mg Elamipretide | 40 mg Elamipretide | Placebo |
|---|---|---|---|
| FatigueGeneral disorders | 2/22 | 1/25 | 1/24 |
| NasopharyngitisInfections and infestations | 1/22 | 2/25 | 1/24 |
| DizzinessNervous system disorders | 1/22 | 1/25 | 1/24 |
| HeadacheNervous system disorders | 1/22 | 0/25 | 0/24 |
| Injection site haemorrhageGeneral disorders | 1/22 | 0/25 | 0/24 |
| ConstipationGastrointestinal disorders | 1/22 | 0/25 | 0/24 |
| NauseaGastrointestinal disorders | 1/22 | 0/25 | 1/24 |
| Renal impairmentRenal and urinary disorders | 1/22 | 0/25 | 0/24 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/22 | 0/25 | 0/24 |
| Gastroenteritis viralInfections and infestations | 1/22 | 0/25 | 0/24 |
Of the 22 subjects in the 4 mg group, 1 subject (1.4%) discontinued from the study due to an AE. One of the subjects randomized to 4mg elamipretide arm was treated with 40mg elamipretide.
| Age, Continuous(years) | 4 mg Elamipretide | 40 mg Elamipretide | Placebo | Total |
|---|---|---|---|---|
| Mean | 65.3 ± 10.76 | 62.6 ± 9.63 | 66.8 ± 9.07 | 64.8 ± 9.83 |
| Sex: Female, Male(Participants) | 4 mg Elamipretide | 40 mg Elamipretide | Placebo | Total |
|---|---|---|---|---|
| Female | 3 | 5 | 9 | 17 |
| Male | 19 | 20 | 15 | 54 |
| Ethnicity (NIH/OMB)(Participants) | 4 mg Elamipretide | 40 mg Elamipretide | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 22 | 24 | 24 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 4 mg Elamipretide | 40 mg Elamipretide | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 22 | 25 | 24 | 71 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Left ventricular end systolic volume(mL) | 4 mg Elamipretide | 40 mg Elamipretide | Placebo | Total |
|---|---|---|---|---|
| Mean | 87.0 ± 38.45 | 79.6 ± 21.54 | 77.7 ± 38.58 | 81.3 ± 33.28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Sep 2017, 15 months.
Results were first posted in Apr 2020, 2 years 7 months after primary completion.
Of 73 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 15 months is below that.
Counting every sponsor, half of 184 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →